newsfilter
← Latest News
Business Wire·

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash